Hypercholesterolemia Treatment Market
Number of pages: 100 | Report Format: PDF | Published date: March 31, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 19.38 billion |
|
Revenue Forecast in 2031 |
US$ 26.41 billion |
|
CAGR |
3.5% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug Type, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global hypercholesterolemia treatment market was valued at US$ 19.38 billion in 2022 and is expected to register a revenue CAGR of 3.5% to reach US$ 26.41 billion by 2031.
Hypercholesterolemia Treatment Market Fundamentals
Hypercholesterolemia is a medical condition characterized by high levels of cholesterol in the blood. High levels of cholesterol can increase the risk of developing heart disease and other health problems. There are two types of cholesterol: low-density lipoprotein (LDL) and high-density lipoprotein (HDL). LDL cholesterol is often referred to as bad cholesterol because it can build up in the walls of arteries and form plaque, narrowing and hardening the arteries, leading to an increased risk of heart disease. Hypercholesterolemia can be caused by a variety of factors, including genetics, diet, and lifestyle habits. Several medications are used to treat hypercholesterolemia, including statins, bile acid sequestrants, niacin, and fibrates. Statins are the most used medication for treating high cholesterol levels, and they work by blocking an enzyme involved in cholesterol production in the liver.
The global hypercholesterolemia treatment market is expected to grow significantly in the coming years, driven by the increasing prevalence of high cholesterol levels, as well as the growing awareness of the risks associated with high cholesterol levels, such as cardiovascular diseases. Several pharmaceutical companies, such as Pfizer, Merck, AstraZeneca, and Amgen, hold incumbency in the global hypercholesterolemia treatment market. These companies invest heavily in research and development to develop new, more effective cholesterol-lowering medications.
[86886]
Hypercholesterolemia Treatment Market Dynamics
The global hypercholesterolemia treatment market is expected to grow significantly in terms of revenue share during the forecast period due to the rising prevalence of hypercholesterolemia worldwide and the increasing demand for effective and safe treatment options. Moreover, the increasing use of statins is another factor driving the market revenue growth to some extent. Statins are the most prescribed medications for treating hypercholesterolemia. They work by blocking an enzyme necessary for cholesterol production in the liver. During the forecast period, the use of statins is expected to increase due to their effectiveness in reducing cholesterol levels and the availability of generic versions.
The rising adoption of PCSK9 inhibitors is also responsible for boosting the global hypercholesterolemia treatment market revenue growth. PCSK9 inhibitors are a new class of drugs used to lower LDL cholesterol levels in patients who cannot tolerate statins or have a genetic condition that causes high cholesterol. These drugs block a protein that prevents the liver from removing LDL cholesterol from the blood. The market for PCSK9 inhibitors is expected to grow rapidly in terms of revenue share due to the increasing demand for alternative treatment options. Many key companies are conducting trials to launch versions of this drug. According to the latest news, beginning in the second half of the year, Merck will launch phase III studies for high cholesterol using the oral PCSK9 inhibitor MK-0616, which will enroll patients for both primary and secondary prevention.
Growing demand for non-pharmacological interventions. Lifestyle modifications such as a healthy diet and regular exercise can also help reduce cholesterol levels in the blood. There is a growing demand for non-pharmacological interventions for hypercholesterolemia, and healthcare professionals are increasingly recommending these interventions to patients. Hypercholesterolemia is a common condition worldwide, and its prevalence is expected to increase further in the coming years due to unhealthy diets, sedentary lifestyles, and increasing obesity rates. The development of advanced cholesterol testing methods, such as lipid profiling and genetic testing, is expected to drive the hypercholesterolemia treatment market revenue to some extent. These methods can help identify individuals at risk of hypercholesterolemia and enable early intervention. The hypercholesterolemia treatment market revenue is expected to continue growing due to the increasing demand for safe and effective treatment options for hypercholesterolemia.
The high cost of existing treatments, a variety of risk-related concerns of medications used for treating hypercholesterolemia, and a lack of diagnostic tools for the condition are the main issues limiting the market's ability to grow in terms of revenue.
Hypercholesterolemia Treatment Market Ecosystem
The global hypercholesterolemia treatment market is analyzed from three perspectives: drug type, distribution channel, and region.
Hypercholesterolemia Treatment Market by Drug Type
[67878]
Based on product type, the global hypercholesterolemia treatment market has been segmented into statins, PCSK9 inhibitors, fibric acid derivatives, bile-acid binding resins, cholesterol absorption inhibitors, and others.
The Statin segment accounts for the largest revenue share in the global hypercholesterolemia treatment market. This sizable revenue growth is owing to the increasing application of statins to treat hypercholesterolemia. Statins are the preferred treatment and best-recognized drug therapy against hypercholesterolemia. Clinicians have long utilized statin medicines to treat hypercholesterolemia, hyperlipoproteinemia, and hypertriglyceridemia as an adjunct to diet and exercise. The principal application of these agents is for the primary and secondary prevention of coronary artery disease. The surging application of medications like simvastatin and atorvastatin further propels the statins segment's revenue growth. Statins are a class of drugs used to lower cholesterol levels in people with hypercholesterolemia, a condition characterized by high levels of cholesterol in the blood. Statins work by inhibiting the enzyme HMG-CoA reductase, which is involved in the production of cholesterol in the liver. By blocking this enzyme, statins reduce the amount of cholesterol that is produced by the liver, leading to lower levels of cholesterol in the blood. Statins are effective in reducing both LDL cholesterol (the "bad" cholesterol) and total cholesterol levels. They have been shown to reduce the risk of heart attacks, strokes, and other cardiovascular events in people with hypercholesterolemia. Statins can also help to stabilize plaques in the arteries, reducing the risk of plaque rupture and subsequent cardiovascular events. Over the years, statins have seen a large revenue growth, especially in Europe and North America.
Hypercholesterolemia Treatment Market by Distribution Channel
Based on distribution channels, the global hypercholesterolemia treatment market is segmented into hospital pharmacies, retail pharmacies, and others.
Hospital pharmacies account for the largest revenue share in the global hypercholesterolemia treatment market. This significant share of revenue is due to cholesterol-lowering drugs, such as statins, and PCSK9 inhibitors, which are mostly prescribed by medical professionals and are preferably purchased through hospital pharmacies by the patients.
Hypercholesterolemia Treatment Market by Region
Based on region, the global hypercholesterolemia treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounts for the largest revenue share in the global hypercholesterolemia treatment market. The growth of this region is owing to the rising incidence of heart ailments and related ailments in the North American region. According to the Center for Disease Control, twenty-eight million adults in the United States have total cholesterol levels above 240 mg/dL. Nearly 7% of U.S. children and adolescents ages 6 to 19 have high total cholesterol. Some key players in the hypercholesterolemia treatment market in North America include Pfizer, Inc., Merck & Co., Inc., AstraZeneca PLC, Sanofi S.A., and Amgen, Inc. These companies are actively engaged in developing and marketing drugs and therapies for hypercholesterolemia treatment in the region.
The hypercholesterolemia treatment market in Europe was experiencing steady growth in terms of revenue share. The market for hypercholesterolemia treatment in Europe is driven by the increasing prevalence of hypercholesterolemia, growing awareness of the risks associated with high cholesterol levels, and the availability of effective treatment options. Statins are the most commonly used class of drugs for treating hypercholesterolemia, accounting for a significant share of the hypercholesterolemia treatment market in Europe.
The hypercholesterolemia treatment market revenue in the Asia Pacific region is expected to grow significantly during the forecast period. Hypercholesterolemia is a condition where there is an elevated level of cholesterol in the blood, which can increase the risk of cardiovascular disease. Asia Pacific is home to a large population, which makes it an attractive market for hypercholesterolemia treatment. Additionally, the increasing prevalence of hypercholesterolemia in the region, particularly in countries such as India and China, is driving demand for effective treatments. Several companies are operating in the hypercholesterolemia treatment market in the Asia Pacific region, including Pfizer, AstraZeneca, Merck & Co., and Amgen. These companies invest in research and development to develop new and innovative treatments for hypercholesterolemia, such as PCSK9 inhibitors and other lipid-lowering agents.
Competitive Landscape of Hypercholesterolemia Treatment Market
Some of the prominent players operating in the global hypercholesterolemia treatment market are: -
Strategic Developments in Hypercholesterolemia Treatment Market
The global hypercholesterolemia treatment market is expected to grow at a revenue CAGR of 3.5% during the forecast period.
Novartis AG, AbbVie Inc., AstraZeneca Plc, Sanofi S.A., and Pfizer Inc are a few key players in the global hypercholesterolemia treatment market.
The statins segment accounts for the largest revenue share in the global hypercholesterolemia treatment market.
North America and Europe account for a prominent revenue share in the global hypercholesterolemia treatment market.
Technological advancements in the treatment of hypercholesterolemia, improved healthcare facilities, a rise in research and drug development for the treatment, government initiatives in spreading awareness about the symptoms, cause, and the available treatment of hypercholesterolemia, and an increase in healthcare investments are expected to rise with a lucrative revenue growth opportunities during the forecast period.
*Insights on financial performance are subject to the availability of information in the public domain